Centessa Pharmaceuticals, a biotech holding company carved out of Medicxi, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Centessa is a biotech holding company that was founded on the observation that "asset-centric" drug development companies experience a higher probability of clinical success. The company's portfolio is comprised of 10 life science companies previously owned by either Medicxi or Index Ventures which represent 16 development programs with clear biological rationale, four of which are in clinical development. The company has stated it expects to present more than 12 clinical readouts over the next three years, including three this year.
The Cambridge, United Kingdom-based company was founded in 2020, while its portfolio companies were founded between 2013 and 2019. Centessa plans to list on the Nasdaq under the symbol CNTA. It filed confidentially on March 15, 2021. Morgan Stanley, Goldman Sachs, Jefferies and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
